Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Research Report 2024

Publication ID:

PB508246588

Publication Date:

August 26, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Tofacitinib citrate extended-release tablets refer to a specific pharmaceutical formulation of tofacitinib citrate,a Janus kinase(JAK)inhibitor used in the treatment of certain autoimmune diseases such as rheumatoid arthritis.
The global Tofacitinib Citrate Extended-Release Tablets market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Tofacitinib Citrate Extended-Release Tablets include Pfizer, Zydus, Sino Therapeutics, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, Lepu Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tofacitinib Citrate Extended-Release Tablets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tofacitinib Citrate Extended-Release Tablets.
The Tofacitinib Citrate Extended-Release Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Tofacitinib Citrate Extended-Release Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tofacitinib Citrate Extended-Release Tablets manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Pfizer
Zydus
Sino Therapeutics
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Yichang Humanwell Pharmaceutical
Sichuan Kelun Pharmaceutical
Lepu Pharmaceutical
Segment by Type
11mg per Tablet
22mg per Tablet
Segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Ulcerative Colitis
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tofacitinib Citrate Extended-Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tofacitinib Citrate Extended-Release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Overview
1.1 Product Definition
1.2 Tofacitinib Citrate Extended-Release Tablets by Type
1.2.1 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 11mg per Tablet
1.2.3 22mg per Tablet
1.3 Tofacitinib Citrate Extended-Release Tablets by Application
1.3.1 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Value by Application (2024-2030)
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriatic Arthritis
1.3.4 Ankylosing Spondylitis
1.3.5 Ulcerative Colitis
1.3.6 Other
1.4 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue 2019-2030
1.4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales 2019-2030
1.4.3 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Competition by Manufacturers
2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Tofacitinib Citrate Extended-Release Tablets, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Product Type & Application
2.7 Global Key Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Date of Enter into This Industry
2.8 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Competitive Situation and Trends
2.8.1 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Tofacitinib Citrate Extended-Release Tablets Players 麻豆原创 Share by Revenue
2.8.3 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Scenario by Region
3.1 Global Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2019-2030
3.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2019-2024
3.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2025-2030
3.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2019-2030
3.3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2019-2024
3.3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2025-2030
3.4 North America Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Facts & Figures by Country
3.4.1 North America Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2030)
3.4.3 North America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Facts & Figures by Country
3.5.1 Europe Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2030)
3.5.3 Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Region (2019-2030)
3.6.3 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2030)
3.7.3 Latin America Tofacitinib Citrate Extended-Release Tablets Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2019-2030)
3.8.3 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2019-2030)
4.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2019-2024)
4.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2025-2030)
4.1.3 Global Tofacitinib Citrate Extended-Release Tablets Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2019-2030)
4.2.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2019-2024)
4.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2025-2030)
4.2.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2019-2030)
5 Segment by Application
5.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2019-2030)
5.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2019-2024)
5.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2025-2030)
5.1.3 Global Tofacitinib Citrate Extended-Release Tablets Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2019-2030)
5.2.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2019-2024)
5.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2025-2030)
5.2.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Zydus
6.2.1 Zydus Company Information
6.2.2 Zydus Description and Business Overview
6.2.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.2.5 Zydus Recent Developments/Updates
6.3 Sino Therapeutics
6.3.1 Sino Therapeutics Company Information
6.3.2 Sino Therapeutics Description and Business Overview
6.3.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.3.5 Sino Therapeutics Recent Developments/Updates
6.4 Qilu Pharmaceutical
6.4.1 Qilu Pharmaceutical Company Information
6.4.2 Qilu Pharmaceutical Description and Business Overview
6.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.4.5 Qilu Pharmaceutical Recent Developments/Updates
6.5 CSPC Ouyi Pharmaceutical
6.5.1 CSPC Ouyi Pharmaceutical Company Information
6.5.2 CSPC Ouyi Pharmaceutical Description and Business Overview
6.5.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.5.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates
6.6 Yichang Humanwell Pharmaceutical
6.6.1 Yichang Humanwell Pharmaceutical Company Information
6.6.2 Yichang Humanwell Pharmaceutical Description and Business Overview
6.6.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.6.5 Yichang Humanwell Pharmaceutical Recent Developments/Updates
6.7 Sichuan Kelun Pharmaceutical
6.7.1 Sichuan Kelun Pharmaceutical Company Information
6.7.2 Sichuan Kelun Pharmaceutical Description and Business Overview
6.7.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.7.5 Sichuan Kelun Pharmaceutical Recent Developments/Updates
6.8 Lepu Pharmaceutical
6.8.1 Lepu Pharmaceutical Company Information
6.8.2 Lepu Pharmaceutical Description and Business Overview
6.8.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
6.8.5 Lepu Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tofacitinib Citrate Extended-Release Tablets Industry Chain Analysis
7.2 Tofacitinib Citrate Extended-Release Tablets Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tofacitinib Citrate Extended-Release Tablets Production Mode & Process
7.4 Tofacitinib Citrate Extended-Release Tablets Sales and 麻豆原创ing
7.4.1 Tofacitinib Citrate Extended-Release Tablets Sales Channels
7.4.2 Tofacitinib Citrate Extended-Release Tablets Distributors
7.5 Tofacitinib Citrate Extended-Release Tablets Customers
8 Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Dynamics
8.1 Tofacitinib Citrate Extended-Release Tablets Industry Trends
8.2 Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Drivers
8.3 Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Challenges
8.4 Tofacitinib Citrate Extended-Release Tablets 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
Zydus
Sino Therapeutics
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Yichang Humanwell Pharmaceutical
Sichuan Kelun Pharmaceutical
Lepu Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.